Research Use Only. Not for human or veterinary therapeutic use. All content is provided for scientific reference and educational purposes only.
LL-37, the sole human cathelicidin antimicrobial peptide (AMP), is constitutively expressed throughout the gastrointestinal tract — from the gastric epithelium through the small intestine to the colon — where it plays fundamental roles in intestinal mucosal immunity, epithelial barrier maintenance, and the complex bidirectional interaction with the gut microbiome. Understanding LL-37’s gastrointestinal biology is essential for research into inflammatory bowel disease (IBD), dysbiosis-driven pathology, intestinal barrier dysfunction, and enteric infection. This deep-dive covers the mechanisms, model systems, and endpoints most relevant to gut microbiome and mucosal immunity research.
LL-37 in the Gastrointestinal Tract
Expression Pattern and Regulation
LL-37/cathelicidin (encoded by the CAMP gene) is expressed in colonocytes, enterocytes, Paneth cells (which also express α-defensins HD-5 and HD-6), goblet cells, and intestinal macrophages. Expression is upregulated by: short-chain fatty acids (SCFAs, particularly butyrate — via HDAC inhibition at the CAMP promoter), vitamin D3/VDR-RXR signalling (direct VDR-binding element in CAMP promoter), and pattern recognition receptor (PRR) engagement including NOD2 activation. Critically, gut microbiota composition shapes LL-37 expression: SCFA-producing commensals (Faecalibacterium prausnitzii, Roseburia intestinalis, Akkermansia muciniphila butyrate producers) drive butyrate-dependent CAMP upregulation, establishing a positive feedback between microbiome health and host defence peptide tone.
LL-37 and the Gut Microbiome Composition
LL-37 is not a simple broad-spectrum antimicrobial in the gut context — its selective activity against microbial species shapes microbiome composition. Research characterising LL-37’s differential antimicrobial activity against gut commensal vs pathobiont species reveals:
- High activity against pathobionts: Enterococcus faecalis, Fusobacterium nucleatum, Clostridium difficile (MIC characterisation by broth microdilution in anaerobic conditions)
- Relative resistance in commensals: Lactobacillus and Bifidobacterium species demonstrate reduced LL-37 susceptibility due to cell wall architecture differences, consistent with LL-37’s selective pathobiont-targeting role
- F. nucleatum suppression: relevant to colorectal cancer research where F. nucleatum drives tumour-associated immune evasion — LL-37 MIC ≤4 μg/mL against CRC-associated F. nucleatum strains
- C. difficile inhibition: MIC/MBC characterisation in relevant growth conditions (in vitro fermentation model, colonic pH 6.0, mucin supplementation to approximate in vivo conditions)
Intestinal Barrier Biology
Tight Junction Regulation
Intestinal barrier integrity depends on tight junction (TJ) proteins including claudin-1, claudin-3, claudin-4, occludin, ZO-1, and junctional adhesion molecule (JAM-A). LL-37 modulates TJ expression and function through EGFR-MAPK pathway activation — the same transactivation mechanism documented in respiratory epithelium. In intestinal epithelial cell (IEC) lines (Caco-2, T84, HT-29), LL-37 treatment increases TEER (transepithelial electrical resistance) — a functional measure of paracellular barrier integrity — and restores TJ protein expression following LPS, TNF-α, or hypoxia-induced barrier disruption.
Research endpoints for LL-37 intestinal barrier research: TEER (Evom2 voltohmmeter with STX-2 electrodes on Transwell inserts), FITC-dextran permeability assay (4 kDa FITC-D at 1 mg/mL apical; basolateral FITC fluorimetry), claudin-1/occludin/ZO-1 immunofluorescence and confocal Z-stack imaging (junctional localisation vs cytoplasmic mislocalisation scoring), and TJ protein quantification by western blot from cell lysate and membrane fractionation.
Mucus Layer and Goblet Cell Biology
The intestinal mucus layer (predominantly MUC2 glycoprotein polymer in the colon) provides a physical barrier between epithelial cells and luminal bacteria. LL-37 is embedded within the mucus layer, creating a zone of antimicrobial activity at the host-microbiome interface. LL-37 stimulates MUC2 expression in goblet cells (HT-29 5F12 goblet cell line, primary colonoid-derived goblet cells) via TLR activation and NF-κB-dependent MUC2 promoter induction.
Research tools: PAS/Alcian Blue mucus staining (histological and ImageJ quantification), MUC2 ELISA from apical conditioned medium, goblet cell proportion quantification (MUC2+ cells per crypt unit by IHC), and electron microscopy of mucus layer thickness in ex vivo intestinal segments.
🔗 Related Reading: For a comprehensive overview of LL-37 research, mechanisms, UK sourcing, and safety data, see our LL-37 Antimicrobial Peptide Research Guide.
Inflammatory Bowel Disease Research Models
LL-37 Dysregulation in IBD
LL-37 expression is paradoxically dysregulated in IBD: elevated in active Crohn’s disease (CD) colonic tissue vs reduced in ulcerative colitis (UC) quiescent mucosa, with inverse patterns in active UC depending on disease location. This context-dependent expression is research-relevant: LL-37’s pro-inflammatory potential (TLR7/8-mediated dendritic cell activation when complexed with self-nucleic acids) may contribute to CD-associated immune dysregulation, while LL-37 deficiency in UC may impair mucosal defence and epithelial repair.
DSS Colitis Model
Dextran sodium sulphate (DSS, 2–5% in drinking water for 5–7 days) disrupts the colonic mucosal barrier — LL-37’s primary functional site — generating an IBD-like phenotype with colon shortening, bloody diarrhoea, weight loss, and histological colitis. The DSS model is particularly suited to LL-37 research because its primary mechanism (barrier disruption allowing bacterial translocation and immune activation) directly engages LL-37’s barrier-protective functions.
DSS endpoints: DAI (Disease Activity Index: weight loss + stool consistency + rectal bleeding, 0–12), colon length (cm, anti-inflammatory endpoint), MPO activity assay (tissue homogenate, Trinder/colorimetric), cytokine multiplex ELISA (IL-6, IL-1β, TNF-α, IL-10, IFN-γ from colonic tissue), histological scoring (Geboes score or modified Baron score: crypt architecture, inflammatory infiltrate, epithelial damage, goblet cell loss), FITC-dextran gut permeability in vivo (oral gavage, serum fluorimetry).
TNBS Colitis Model
Trinitrobenzenesulphonic acid (TNBS) intrarectal instillation generates a hapten-driven CD-like transmural colitis with Th1/Th17 immune profile (contrasting DSS’s predominantly innate/Th2 profile). LL-37’s modulation of Th1/Th17 vs Treg balance via DC activation and cytokine polarisation is relevant here. Endpoints: TNBS survival curve, weight loss trajectory, colonoscopy (endoscopic score), IL-12p70/IL-17A/IFN-γ/TGF-β1/IL-10 multiplex from mesenteric lymph node splenocytes (restimulation ELISPOT and ELISA), and CD4+FoxP3+ Treg flow cytometry of lamina propria lymphocyte (LPL) isolate.
Organoid/Colonoid Systems
Patient-derived intestinal organoids (colonoids from IBD vs healthy surgical resection biopsies) allow LL-37 research in a genetically relevant human tissue context. Standard colonoid assays for LL-37 biology: TEER-equivalent Matrigel dome resistance, TNF-α-driven barrier disruption rescue (LL-37 pre-treatment), CAMP gene expression by RT-qPCR (baseline and butyrate/VitD3-stimulated), and single-cell RNA-seq transcriptome comparison of LL-37-treated vs vehicle colonoids for pathway resolution.
Enteric Pathogen Research
C. difficile Infection Biology
Clostridioides difficile (CDI) is a major enteric pathogen, particularly post-antibiotic disruption of gut microbiome. LL-37’s antimicrobial activity against C. difficile vegetative cells and spores, combined with its epithelial barrier-protective function (preventing toxin A/B mucosal access), positions it as a relevant research tool for CDI biology. Assay systems: anaerobic broth microdilution (BHI, 37°C anaerobic chamber), ex vivo colonoid monolayer infection (toxin A/B-GFP fusion reporter, TEER measurement over 24h), and in vivo CDI mouse model (antibiotic cocktail pre-treatment, C. difficile spore gavage, LL-37 treatment pre/post, CFU faecal culture, caecal histology, toxin A ELISA from caecal content).
Salmonella and Invasive Pathogen Defence
Salmonella enterica serovar Typhimurium infection of intestinal epithelium involves invasion of M cells and enterocytes via type III secretion system (T3SS). LL-37 disrupts S. Typhimurium membranes at MIC 2–8 μg/mL (LB broth) and can interfere with T3SS-mediated invasion (invasion assay: gentamicin protection assay in Caco-2 cells, CFU counting). The ASF (altered Schaedler flora) or germ-free mouse colonised with specific commensals allows investigation of CAMP-driven luminal LL-37 levels in determining Salmonella colonisation resistance.
LL-37 and Gut-Brain Axis
The gut-brain axis is modulated by mucosal immune signals including AMPs. LL-37 activates enteric glia (GFAP+ cells in the myenteric plexus) via FPR2/FPRL1 receptor signalling, influencing neurotransmitter release and ENS (enteric nervous system) activity. In germ-free and antibiotic-treated mice — which show reduced LL-37 expression and altered ENS physiology — LL-37 administration may restore gut motility patterns and mucosa-ENS communication. Research endpoints: spatiotemporal mapping (STM) of colonic propagating contractions, FPR2 expression in myenteric ganglia (IHC), and enteric glial GFAP/S100β/p75NTR phenotyping.
Dysbiosis Research Paradigm
LL-37 deficiency (CAMP KO mouse model, or butyrate depletion via antibiotic-induced microbiome disruption) generates a predictable dysbiosis pattern: expansion of pathobionts, reduced commensal diversity, impaired barrier function. 16S rRNA amplicon sequencing (V3-V4 region, Illumina MiSeq; ASV analysis by QIIME2/DADA2) of faecal and mucosal-adherent microbiome provides microbiome composition endpoints. Shotgun metagenomics (Illumina short-read or Oxford Nanopore long-read) allows functional metagenome analysis — KEGG pathway mapping, antibiotic resistance gene inventory, bacteriocin biosynthesis gene identification.
LL-37 repletion (subcutaneous, intrarectal, or oral delivery in enteric-coated formulations for research purposes) in CAMP KO or dysbiotic models and assessment of microbiome restoration provides a controlled experimental framework for LL-37’s microbiome-regulatory role.
Research Applications Summary
| Research Area | Model System | Key Endpoints |
|---|---|---|
| Intestinal barrier integrity | Caco-2/T84 Transwell, colonoid ALI | TEER, FITC-dextran, claudin/ZO-1/occludin IHC |
| IBD — DSS colitis | DSS 2.5% C57BL/6 7 days | DAI, colon length, MPO, cytokine multiplex, Geboes |
| IBD — TNBS colitis | TNBS intrarectal SJL/C57BL/6 | IL-12p70, IL-17A, IFN-γ, Treg flow, histology |
| C. difficile infection | Anaerobic MIC/ex vivo/in vivo CDI | CFU, toxin A/B, TEER, caecal histology |
| Gut microbiome composition | CAMP KO, antibiotic dysbiosis | 16S rRNA amplicon, Shannon diversity, pathobiont CFU |
| Mucus and goblet cell biology | HT-29 5F12, primary colonoid | MUC2 ELISA, PAS staining, goblet cell proportion |
| Gut-brain axis | ENS wholemount, SPM | Contraction pattern, FPR2-GFAP enteric glia |
Regulatory Considerations
Gut microbiome research using germ-free or gnotobiotic mice requires specialised facilities (flexible film isolators, sterile housing). Metagenomic sequencing data handling requires data governance compliance. All in vivo colitis models require Home Office Project Licence under ASPA 1986 with appropriate humane endpoints defined (maximum DAI score, body weight loss thresholds). C. difficile in vivo work requires Hazard Group 2 containment (CL-2). LL-37 for cell culture research requires endotoxin testing <0.1 EU/mL to prevent LPS-driven barrier disruption confounding.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified LL-37 for research and laboratory use. View UK stock →
All information presented is for scientific research and educational purposes only. LL-37 is not approved for human therapeutic use. Research must be conducted in compliance with applicable institutional, regulatory, and ethical guidelines.
